Progenity, Inc.
4330 La Jolla Village Drive
Suite 200
San Diego
California
92122
United States
Website: https://www.progenity.com/
About Progenity, Inc.
Progenity is a biotechnology company with a market-leading presence in Women’s Health molecular testing and a pipeline of proprietary tests and therapeutic applications under development. Progenity has a portfolio of innovative technologies and tests for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and noninvasive prenatal testing (NIPT), all designed to support clinicians in providing excellent patient care.
YEAR FOUNDED:
2002
JOBS:
10 articles with Progenity, Inc.
-
Progenity Reaches Resolution with Government Related to Past Business, Promotional, and Billing Practices
7/23/2020
Progenity, Inc. announced that it has entered into agreements with the Department of Justice and the Department of Health and Human Services that resolve civil and criminal investigations by such agencies related to certain past business, promotional, and billing practices.
-
BioSpace Movers & Shakers, May 29
5/29/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Movers & Shakers, May 1
5/1/2020
Life sciences and pharma companies strengthen their leadership teams and board with this week's Movers & Shakers. -
BioSpace Movers & Shakers, Oct. 25
10/25/2019
Pharma and life sciences companies strengthen their executive and leadership teams with this week's appointments. -
BioSpace Movers and Shakers, Aug. 9
8/9/2019
Biopharma companies strengthen their senior leadership teams and boards of directors. -
BioSpace Movers and Shakers, June 7
6/7/2019
Pharma and biotech companies strengthen their executive and leadership teams with new appointments. -
BioSpace Movers and Shakers: March 1
3/1/2019
Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more. -
Progenity to Present at Three Key Investor Conferences
2/25/2019
Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, announced that Harry Stylli, Ph.D., CEO, will be participating in several upcoming investor conferences.
-
Progenity Announces Expansion of Board of Directors
2/21/2019
Company Focused on Diagnostic and Therapeutic Precision Medicine Solutions in Prenatal and Perinatal Healthcare, Oncology, and Gastroenterology
-
Progenity snagged $125M in funding that will allow the company to accelerate development of its gastrointestinal platform.